Kidney Disease Following Hematopoietic Stem Cell Transplantation

Ala Abudayyeh; Rimda Wanchoo

doi:10.1053/j.ackd.2021.11.003

Kidney Disease Following Hematopoietic Stem Cell Transplantation

Ala Abudayyeh, Rimda Wanchoo

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.

Original language	English (US)
Pages (from-to)	103-115.e1
Journal	Advances in Chronic Kidney Disease
Volume	29
Issue number	2
DOIs	https://doi.org/10.1053/j.ackd.2021.11.003
State	Published - Mar 2022

Keywords

Acute kidney injury
Allogeneic stem cell transplant
Chronic kidney disease
Hepatic sinusoidal obstruction
Thrombotic microangiopathy

ASJC Scopus subject areas

Nephrology

Access to Document

10.1053/j.ackd.2021.11.003

Cite this

@article{a062044f72464c34b45fa257f881efe0,

title = "Kidney Disease Following Hematopoietic Stem Cell Transplantation",

abstract = "Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.",

keywords = "Acute kidney injury, Allogeneic stem cell transplant, Chronic kidney disease, Hepatic sinusoidal obstruction, Thrombotic microangiopathy",

author = "Ala Abudayyeh and Rimda Wanchoo",

note = "Funding Information: We thank Kenar Jhaveri, MD, for creating Figures 1 and 2 using biorender.com. Publisher Copyright: {\textcopyright} 2021 National Kidney Foundation, Inc.",

year = "2022",

month = mar,

doi = "10.1053/j.ackd.2021.11.003",

language = "English (US)",

volume = "29",

pages = "103--115.e1",

journal = "Advances in Chronic Kidney Disease",

issn = "1548-5595",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Kidney Disease Following Hematopoietic Stem Cell Transplantation

AU - Abudayyeh, Ala

AU - Wanchoo, Rimda

PY - 2022/3

Y1 - 2022/3

N2 - Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.

AB - Hematopoietic stem cell transplantation (SCT) provides a curative option for the treatment of several malignancies. Its growing use is associated with an increased burden of kidney disease. Acute kidney injury is usually seen within the first 100 days of transplantation and has an incidence ranging between 12 and 73%, with the highest rate in myeloablative allogeneic SCT. A large subset of patients after SCT develop chronic kidney disease. They can be broadly classified into thrombotic microangiopathy, nephrotic syndrome, and calcineurin toxicity. Dialysis requirement after SCT is associated with mortality exceeding 80%. Given the higher morbidity and mortality related to development kidney disease, nephrologists need to be aware of the various causes and best treatment options.

KW - Acute kidney injury

KW - Allogeneic stem cell transplant

KW - Chronic kidney disease

KW - Hepatic sinusoidal obstruction

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=85133756587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133756587&partnerID=8YFLogxK

U2 - 10.1053/j.ackd.2021.11.003

DO - 10.1053/j.ackd.2021.11.003

M3 - Review article

C2 - 35817518

AN - SCOPUS:85133756587

SN - 1548-5595

VL - 29

SP - 103-115.e1

JO - Advances in Chronic Kidney Disease

JF - Advances in Chronic Kidney Disease

IS - 2

ER -

Kidney Disease Following Hematopoietic Stem Cell Transplantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this